ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
Launched by ATRICURE, INC. · Sep 24, 2012
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
This prospective, open label, multi-center, observational, single arm registry is designed to monitor the AtriCure Synergy Ablation System continued safety and efficacy during the peri-procedural and long-term phase during commercial use in patients being treated for non-paroxysmal forms of atrial fibrillation who are undergoing a concomitant open, on-pump cardiac surgical procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> or equal to 18 years of age
- * History of non-paroxysmal form of Atrial Fibrillation (AF) as defined by the Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society Consensus Statement:
- • Persistent AF shall be defined as continuous AF that is sustained beyond seven days. Episodes of AF in which a decision is made to electrically or pharmacologically cardiovert the patient after greater than or equal to 48 hours of AF but prior to 7 days, should also be classified as persistent AF episodes.
- • Longstanding persistent AF shall be defined as continuous AF of greater than 12 months duration. The performance of a successful cardioversion (sinus rhythm \>30 seconds) within 12 months of an ablation procedure with documented early recurrence of AF with 30 days should not alter the classification of AF as longstanding persistent.
- • Subject is scheduled to undergo elective open cardiac surgical procedure(s) to be performed on cardiopulmonary bypass for one or more of the following: Coronary Artery Bypass Grafting, Mitral valve repair or replacement, Aortic valve repair or replacement, Tricuspid valve repair or replacement. In conjunction with these procedure patent foramen ovale (PFO) or atrial septal defect (ASD) repair are allowed.
- • The patient (or their legally authorized representative) agrees to participate in this study by singing the Institutional Review Board (IRB) approved informed consent form.
- • Willing and able to return for scheduled follow up visits.
- Exclusion Criteria:
- • Stand along AF without indication(s) for concomitant cardiac surgery.
- • Need for emergent cardiac surgery (i.e., cardiogenic shock).
- • Preoperative need for an intra-aortic balloon pump or intravenous inotropes.
- • Pregnancy or desire to get pregnant for the duration of the study concomitant surgical procedure through the thirty six (36) month follow up period).
- • Enrolled in another clinical trial that could confound the results of this study.
About Atricure, Inc.
AtriCure, Inc. is a leading medical device company focused on developing innovative solutions for the treatment of atrial fibrillation and other cardiac conditions. With a commitment to advancing cardiac surgery and improving patient outcomes, AtriCure specializes in technologies that address the complexities of heart rhythm disorders. The company's portfolio includes a range of devices and therapies designed to facilitate atrial fibrillation management and enhance surgical techniques. Through rigorous clinical trials and a dedication to research, AtriCure aims to provide healthcare professionals with effective tools to optimize patient care in the field of electrophysiology and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Cleveland, Ohio, United States
Saint Petersburg, Florida, United States
Portland, Maine, United States
Royal Oak, Michigan, United States
Toledo, Ohio, United States
Traverse City, Michigan, United States
Norfolk, Virginia, United States
San Diego, California, United States
Grand Forks, North Dakota, United States
Pittsburgh, Pennsylvania, United States
Memphis, Tennessee, United States
Saint Louis, Missouri, United States
Hartford, Connecticut, United States
Portland, Oregon, United States
Saint Louis, Missouri, United States
Charlotte, North Carolina, United States
Richmond, Virginia, United States
Seattle, Washington, United States
Birmingham, Alabama, United States
Paterson, New Jersey, United States
Los Angeles, California, United States
Los Angeles, California, United States
Salt Lake City, Utah, United States
Wausau, Wisconsin, United States
Charlotte, North Carolina, United States
Grand Rapids, Michigan, United States
Philadelphia, Pennsylvania, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Lincoln, Nebraska, United States
Fort Myers, Florida, United States
Saint Petersburg, Florida, United States
Lansing, Michigan, United States
Scottsdale, Arizona, United States
West Hollywood, California, United States
Gainesville, Florida, United States
Tampa, Florida, United States
Evanston, Illinois, United States
Springfield, Illinois, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
West Roxbury, Massachusetts, United States
Minneapolis, Minnesota, United States
Asheville, North Carolina, United States
Greensboro, North Carolina, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Harrisburg, Pennsylvania, United States
Dallas, Texas, United States
Patients applied
Trial Officials
Patrick McCarthy, MD
Study Chair
Chief, Division of Cardiac Surgery, Northwestern University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials